Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626555 | 0.88 | BACE1 (0.48) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1624032 | 0.88 | BACE1 (0.50) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1624299 | 0.86 | KCNK3 (0.50) | BACE1MEN1HTTKMT2A | |
| SCHEMBL27756789 | 0.86 | SMO (0.38) | MEN1HTTKMT2AGSK3AGSK3B | |
| SCHEMBL1625115 | 0.86 | BACE1 (0.50) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1625618 | 0.86 | BACE1 (0.48) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1624938 | 0.86 | BACE1 (0.54) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1624462 | 0.85 | LMNA (0.56) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1625089 | 0.85 | BACE1 (0.46) | BACE1MEN1HTTKMT2A | |
| SCHEMBL1623242 | 0.85 | BACE1 (0.46) | BACE1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | claimed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | claimed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | claimed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | GLI1, SHH, SMO | BACE1 2113/4885JAK2 686/4885JAK1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.